ZIRWAS, M.; DRAELOS, Z.; DUBOIS, J.; KIRCIK, L. .; MOORE, A.; STEIN GOLD, L.; ALONSO-LLAMAZARES, J. .; BUKHALO, M.; BRUCE, S.; EADS, K.; GREEN, L.; GUENTHNER, S.; FERRIS, L.; FORMAN, S.; KEMPERS, S.; LAIN, E. .; LYNDE, C.; PARISER, D.; PARISER, D.; TOTH, D.; YAMAUCHI, paul; BURNETT, P.; BERK, D. A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 5, n. 6, p. s94, 2021. DOI: 10.25251/skin.5.supp.94. Disponível em: https://jofskin.org/index.php/skin/article/view/1445. Acesso em: 11 aug. 2022.